Abbott and Beta Bionics Partner to Advance Diabetes Management

Abbott Laboratories has announced a new partnership in the diabetes technology space, collaborating with Beta Bionics, the company behind the iLet Bionic Pancreas. The agreement will integrate Abbott's FreeStyle Libre Continuous Glucose Monitor (CGM) with the iLet Bionic Pancreas, an autonomous insulin delivery system that simplifies diabetes management for patients and physicians alike.

The iLet Bionic Pancreas offers a more convenient and less burdensome way to manage type 1 diabetes, and the collaboration with Abbott allows users to customize their diabetes management experience using a trusted CGM. Sean Saint, CEO of Beta Bionics, emphasized the importance of providing options for users, stating that the partnership will enable patients to choose the CGM that best fits their needs.

Set to launch in the second quarter of 2024, the integration of the iLet with the FreeStyle Libre 3 Plus will be the first automated insulin delivery (AID) system to feature this technology in the U.S. A simple software update will allow users to choose their CGM when setting up a new sensor, offering greater flexibility in diabetes care.

The partnership also simplifies access to the iLet and FreeStyle Libre 3 Plus through pharmacy sales and a pay-as-you-go model. Additionally, the system will be available via durable medical equipment distributors. This collaboration follows another recent high-profile partnership for Abbott in the diabetes tech industry—an August agreement with Medtronic, where Abbott will design a CGM that Medtronic will market and sell.